Copyright 2024 All rights reserved.

Core Technology

We have developed and established all core technologies by ourselves

for the whole process from R&D to mass production of immune-tolerized EV therapeutics.

Core Technology

Mass Production of immune-tolerized EVs

Stemmedicare's cell culture platform technology is the only technology that can establish an immune-tolerized cell line with HLA-G expression and secretion characteristics regardless of cell origin. In addition, the immune-tolerized cell line expressing HLA-G is a cell line with significantly improved EV secretion ability as well as cell proliferation. Moreover, the EV isolation technology developed by Stemmedicare is also an innovative technology that can separate EVs with much higher purity and without any physical damage or impurities compared to commercial isolation methods.

Platform Technology for mass production of

HLA-G+ EVs not causing immune responses

  • OPTIONA

    Ex-vivo culture system simulating

    pregnancy environment

  • OPTIONB

    Optimal Temperature Profile with

    circulation for cell culture

  • OPTIONC

    Serum-free 3D culture matrix for

    improved cell proliferation

  • OPTIOND

    EV isolation with higher purity than

    commercial isolation methods